Metis Global Partners LLC Sells 5,008 Shares of Stryker Corporation $SYK

Metis Global Partners LLC decreased its stake in shares of Stryker Corporation (NYSE:SYK) by 25.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,389 shares of the medical technology company’s stock after selling 5,008 shares during the period. Metis Global Partners LLC’s holdings in Stryker were worth $5,693,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker during the second quarter valued at approximately $26,000. Sachetta LLC lifted its holdings in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares in the last quarter. Ridgewood Investments LLC lifted its holdings in Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new position in Stryker in the 1st quarter valued at $37,000. Finally, Solstein Capital LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at $43,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 in the last three months. 5.90% of the stock is owned by company insiders.

Stryker Stock Performance

Shares of SYK stock opened at $355.74 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $136.04 billion, a PE ratio of 47.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The stock has a 50-day moving average of $374.63 and a 200-day moving average of $381.22. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Wall Street Analyst Weigh In

SYK has been the topic of several research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Evercore ISI cut their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Fourteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.